Intraperitoneal Atomization of Levobupivacaine During Gynaecological Laparoscopic Procedures ; Impact on Pain, Opioid Use and Length of Recovery Room Stay (IPLA).
- Conditions
- Pain, Postoperative
- Interventions
- Drug: Additional injection of 0,5% levobupivacaine.Drug: Intraperitoneal atomization of levobupivacaine.
- Registration Number
- NCT01886352
- Lead Sponsor
- University Hospital, Ghent
- Brief Summary
In this study, we will compare 3 treatments. The first group of patients will receive the standard treatment (paracetamol, diclofenac and an opioid if necessary) with infiltration of the portal sites with the local anesthetic ( 0.5% levobupivacaine) . The second group of patients will receive the standard of care, with infiltration of the portal sites with the local anesthetic ( 0.5% levobupivacaine) and additional injection of the local anesthetic ( 0.5% levobupivacaine, non -diluted) in the peritoneal cavity via a trocar both at the beginning and the end of the surgery . The third group of patients will receive the standard of care, with infiltration of the portal sites with the local anesthetic ( 0.5% levobupivacaine) and additional intraperitoneal atomization of the local anesthetic. We will use non-diluted 0.5% levobupivacaine delivered directly onto the target sites both at the beginning and the end of surgery. The drug will be delivered using OptiSpray® surgical spray device, an inexpensive delivery system that will direct a fine mist of drug directly to the areas of the peritoneal cavity that are theoretically the cause of post-op pain (diaphragms, peritoneal abdominal surface, surgical dissection site).
Our primary goal is to assess the efficacy of intraperitoneal atomization of levobupivacaine in reducing postoperative pain and of opioid requirements in patients undergoing gynecological laparoscopic procedures in one-day surgery.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 16
- Patients who are planned for gynaecological laparoscopic interventions on an ambulatory basis.
- Less than 18 year old.
- Weight less than 50 kg and more than 80 kg.
- Pregnant.
- Prisoners;
- Allergic to topical anesthetics (Amides specifically).
- Allergic to Opioids as a class.
- Currently or within the last 30 days been prescribed an opiate medication.
- Chronic pain syndrome.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Additional injection of 0.5% levobupivacaine via a trocar Additional injection of 0,5% levobupivacaine. The second group of patients will receive the standard of care, with infiltration of the portal sites with the local anesthetic ( 0.5% levobupivacaine) and additional injection of the local anesthetic ( 0.5% levobupivacaine, non -diluted) in the peritoneal cavity via a trocar both at the beginning and the end of the surgery. Additional intraperitoneal atomization of levobupivacaine. Intraperitoneal atomization of levobupivacaine. The third group of patients will receive the standard of care, with infiltration of the portal sites with the local anesthetic ( 0.5% levobupivacaine) and additional intraperitoneal atomization of the local anesthetic. Infiltration of portal sites with 0,5% levobupivacaine. Standard Injection of Levobupivacaine in portal sites. The first group of patients will receive the standard treatment (paracetamol, diclofenac and an opioid if necessary) with infiltration of the portal sites with the local anesthetic ( 0.5% levobupivacaine). Additional injection of 0.5% levobupivacaine via a trocar Standard Injection of Levobupivacaine in portal sites. The second group of patients will receive the standard of care, with infiltration of the portal sites with the local anesthetic ( 0.5% levobupivacaine) and additional injection of the local anesthetic ( 0.5% levobupivacaine, non -diluted) in the peritoneal cavity via a trocar both at the beginning and the end of the surgery. Additional intraperitoneal atomization of levobupivacaine. Standard Injection of Levobupivacaine in portal sites. The third group of patients will receive the standard of care, with infiltration of the portal sites with the local anesthetic ( 0.5% levobupivacaine) and additional intraperitoneal atomization of the local anesthetic.
- Primary Outcome Measures
Name Time Method Post-operative pain intensity after laparoscopic gynaecological surgery in 1-day hospital setting. Participants will be followed for the duration of hospital stay, an expected average of 1 day. Pain evaluation will be done using an 11-point numeric rating scale (0 = no pain, 10 = worst pain possible).
Post-operative shoulder pain after laparoscopic gynecological procedure in 1-day hospital setting. Participants will be followed for the duration of hospital stay, an expected average of 1 day. Pain evaluation will be done using an 11-point numeric rating scale (0 = no pain, 10 = worst pain possible).
- Secondary Outcome Measures
Name Time Method Post-operative opioid analgesic requirements after laparoscopic gynaecological surgery. Participants will be followed for the duration of hospital stay, an expected average of 1 day. Piritramide 0,05 mg/kg
Post-operative shoulder pain after laparoscopic gynecological surgery from hospital discharge until 24 hrs post-operatively. Patients will be followed until 24 hours post-operatively. Patients will be asked to evaluate their pain at 6 hrs, 12 hrs, 18 hrs and 24 hrs post-operatively using an 11-point numeric rating scale (0=no pain and 10= worse pain possible) and report it by telephone.
Time until discharge from hospital. Patients will be followed until an estimated 24 hours post-operatively. Discharge criterion : modified aldrete ≥ 12/14.
Time until discharge from recovery room. Up until discharge from recovery room post-operatively, probably a few hours. Discharge criterion: aldrete ≥ 9/10.
Post-operative pain intensity after laparoscopic gynaecological surgery from hospital discharge until 24 hrs post-operatively. Patients will be followed until 24 hours post-operatively. Patients will be asked to evaluate their pain at 6 hrs, 12 hrs, 18 hrs and 24 hrs post-operatively using an 11-point numeric rating scale (0=no pain and 10= worse pain possible) and report it by telephone.
Post-operative nausea and vomiting (PONV) in the first 24 hrs post-operatively, after laparoscopic gynecological surgery. Patients will be followed until 24 hours post-operatively. Nausea and vomiting will be evaluated every 15' during the first 2 hrs, every 30' until hospital discharge, using a PONV verbal descriptor scale 0 to 2 points : 0=no nausea, 1=any nausea, 2 =vomiting. After discharge, patients wil be asked to evaluate PONV at 6 hrs, 12 hrs, 18 hrs and 24 hrs post-operatively and report it by telephone.
Post-operative sedation until hospital discharge, after laparoscopic gynecological surgery. Patients will be followed up to 6 hrs post-operatively. Sedation will be evaluated at 0, 1, 2, 4, 6 hrs post-operatively, using the Ramsay sedation score (1= anxious and agitated, 2= cooperative, tranquil, oriented, 3=responds only to verbal commands, 4= asleep with brisk response to light stimulation, 5=asleep without response to light stimulation, 6=non-responsive).
Trial Locations
- Locations (1)
Ghent University Hospital
🇧🇪Ghent, Belgium